🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Do you have #diabetes? Do you know someone with diabetes? Register now to secure your FREE place at this important event at Fed Square in Melbourne on Tuesday 14 Nov at 6pm #EndDiabetesStigma

Join us for the November Beyond Insulin seminar, next Thursday November 23 at 1pm - 2pm AEST Speaker: Prof Natasha Rogers Title: CD47 – more than just a receptor on islets No registration necessary, all welcome! More info here: atic.svi.edu.au/news-events/cd…

Congratulations ATIC clinical trials lead, Associate Professor John Wentworth and the Type1 Screen team from The Royal Melbourne Hospital and WEHI (Walter and Eliza Hall Institute) for their commitment to equity in screening for #t1d. The at-home blood test was FINALIST in the Victorian Department of Health Victorian DoH Awards!

Some important progress in autoimmune type 1 diabetes with a potent anti-inflammatory agent—baricitinib—preserving pancreas β-islet cell function in a small, randomized, placebo-controlled trial nejm.org/doi/full/10.10… NEJM

This line in the accompanying editorial sums up why: "The incidence of type 1 diabetes has tripled, its cause remains unknown, its prevention is still not possible, and its cure—nil." nejm.org/doi/full/10.10…

A new trial in NEJM from Thomas Kay, MBBS, PhD, of SVIResearch, and colleagues suggests use of baricitinib (Olumiant; Eli Lilly and Company) was associated with the preservation of beta-cell function among people with new-onset #Type1Diabetes. hcplive.com/view/study-fin… #T1D

Type 1 diabetes game changer - ATIC researchers led by Professor’s Thomas Kay and Helen Thomas have shown that a daily tablet of baricitinib can preserve beta cell function in people with newly diagnosed #T1D.

Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes | NEJM nejm.org/doi/full/10.10… Great to see this just published showing a new potential benefit of jak inhibitors Gavegnano Group WesElyMD Raymond Schinazi @Boghuma Andre Kalil, MD MPH

A new study has found a drug used to treat immune diseases like rheumatoid arthritis could help preserve insulin function and suppress the progression of Type 1 diabetes. The findings of the BANDIT trial were published in the NEJM today. thermh.org.au/news/common-dr…

Jak inhibitors demonstrate efficacy in new onset T1D. nejm.org/doi/full/10.10… nejm.org/doi/full/10.10…

🚨RESEARCH BREAKTHROUGH🚨 A @JDRF-funded, world-first clinical trial in Australia, has shown that a commonly prescribed drug (#baricitinib) can suppress the progression of #Type1Diabetes in those newly diagnosed with #T1D! 🔗 bit.ly/3RvbTPq @JDRFaus #GBDoc #Research

Exciting results! Let the floodgates open for #type1diabetes disease modifying therapeutics! Kudos to the BANDIT team and its amazing leadership Tom Kay SVIResearch @JDRF

Exciting type 1 diabetes (T1D) research news! A JDRF-funded clinical trial, published in the renowned New England Journal of Medicine, demonstrated that baricitinib-a JAK inhibitor, which is critical to signaling pathways within both immune cells and beta cells (1/2)

Big T1D research news out of Australia! Immune therapy baricitinib preserves beta cell function in newly diagnosed T1Ds.